MyFinsight
Home
About
Contact
Back
Income Statement
LIGAND PHARMACEUTICALS INC (LGNDZ)
source: myfinsight.com
Download
Download image
Financial Royalty Other
$428K
QARZIBA
$5,885K
Evomela
$1,465K
Filspari
$6,578K
Kyprolis
$8,803K
Royalty Intangible
Other
$5,433K
Rylaze
$2,864K
Teriparatide Injection
$2,298K
Vaxneuvance
$2,643K
Contract And Revenue
Income Other
$1,017K
Milestone And Other
$1,926K
Financial Royalty Assets
$6,313K
Intangible Royalty Assets
$30,084K
Contract Revenue And
Other Income
$2,943K
Material Sales Captisol
$8,287K
Royalty
$36,397K
Gain (loss) from
short-term investments
$939K
Interest income
$1,621K
Other non-operating
expense, net
$1,372K
Total revenues and
other income
$47,627K
Total non-operating
income (expenses), net
$2,779K
Operating income (loss)
$8,444K
Interest expense
$1,153K
Total operating costs
and expenses
$39,183K
Income (loss) before
income taxes
$11,223K
Cost of captisol
$2,907K
Amortization of intangibles
$8,258K
Fair value
adjustments to partner...
-$1,276K
General and
administrative
$20,175K
Research and development
$6,567K
Net income (loss)
$4,847K
Income tax (expense)
benefit
$6,376K
Back